FDA accepted for Priority Review the BLA for V114, Merckメs investigational 15-valent pneumococcal conjugate vaccine
On Jan. 12, 2021, Merck announced the FDA accepted for priority review a Biologics License Application (BLA) for…
On Jan. 12, 2021, Merck announced the FDA accepted for priority review a Biologics License Application (BLA) for…
On Jan. 12, 2021, Abbott announced it had received FDA 510(k) clearance for the first rapid handheld traumatic…
On Jan. 12, 2021, the WHO announced that global scientists were intensifying research into COVID-19 to expand its…
On Jan. 12, 2021, UC Berkeley HIV researchers announced that they had determined the atomic structure of a…
On Jan. 12, 2021, Regeneron announced that the U.S. Department of Health and Human Services (HHS) and the…
On Jan. 11, 2021, CureVac announced the publication of preclinical data demonstrating the induction of robust antibody and…
On Jan. 11, 2021, Abbott announced it had received FDA 510(k) clearance for the first rapid handheld traumatic…
On Jan. 11, 2021, the FDA conditionally approved Anivive Lifesciences’ Laverdia-CA1 (verdinexor tablets) to treat dogs with lymphoma,…
On Jan. 10, 2021, Humanigen announced that they were partnering to make lenzilumab available to hospitalized and hypoxic…
On Jan. 8, 2021, the FDA alerted clinical laboratory staff and health care providers that it was monitoring…
On Jan. 7, 2021, PerkinElmer and Oxford Immunotec announce an agreement under which PerkinElmer acquired Oxford Immunotec for…
On Jan. 7, 2021, Oragenics announced entering into a material transfer agreement with Adjuvance Technologies for use of…
On Jan. 7, 2021, LabCorp announced that it had been awarded a contract from the Centers for Disease…
On Jan. 7, 2021, BioNTech announced publication of preclinical data on its novel mRNA vaccine approach against autoimmune…
On Jan. 6, 2021, the U.S. Department of Health and Human Services (HHS) announced the Centers for Disease…
On Jan. 6, 2021, Bayer announced it had signed a collaboration and services agreement with CureVac, a biopharmaceutical…
On Jan. 5, 2021, the National Institute of Allergy and Infectious Diseases (NIAID) announed that a phase 2/3…
On Jan. 5, 2021, AIM ImmunoTech announced that the active AMP-511 Expanded Access Program (EAP) had dosed its…
On Jan. 4, 2021, the FDA announced that the two different mRNA vaccines were shown remarkable effectiveness of…
On Jan. 4, 2021, Audrey Winkelsas, a 2015 NIH Oxford-Cambridge Scholars Program doctoral student with spinal muscle atrophy…
Greek philosopher Theophrastus (371-287 BCE), the “Father of Botany” wrote of Greeks rotating their staple crops with broad…
On Dec. 30, 2020, Bausch Health announced that the Office for Registration of Medicinal Products, Medical Devices and…
On Dec. 30, 2020, the NIH researchers announced that an in-depth study of how COVID-19 affects a patientメs…
On Dec. 30, 2020, the COVID-19 vaccine developed by Oxford University/AstraZeneca was given regulatory approval by the UK…
On Dec. 29, 2020, Emergent BioSolutions and Mount Sinai Health System announced initiation of the clinical program to…
On Dec. 29, 2020, Regeneron announced encouraging initial data from an ongoing Phase 1/2/3 clinical trial of the…
On Dec. 28, 2020, the FDA approved the first generic of glucagon for injection USP, 1 mg/vial packaged…
On Dec. 28, 2020, Soligenix announced that the National Institute of Allergy and Infectious Diseases (NIAID), had awarded…
On Dec. 24, 2020, AIM ImmunoTech announced that the post-COVID-19 モLong Haulerヤ portion of the active AMP-511 Expanded…
On Dec. 23, 2020, Merck announced an agreement with the U.S. Government to support the development, manufacture and…